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Abstract
Background: PMP22, a member of the GAS3 family of tetraspan proteins, is associated with a variety of
neurological diseases. Previous studies have shown that PMP22 is expressed in proliferative endometrium, but its
function within this tissue is poorly understood. In this study, we first characterized the expression of PMP22 in the
human menstrual cycle and began to characterize its function in the endometrium.
Methods: Using a combination of immunohistochemistry and quantitative PCR, we characterized the expression of
PMP22 in both proliferative and secretory endometrium. Differences in PMP22 expression between proliferative and
secretory endometrium were determined using a Mann-Whitney U test. In order to investigate the influence of
PMP22 on a6 integrin expression, cells were created that ectopically overexpressed PMP22 or expressed a siRNA to
inhibit its expression. These cells were analyzed for changes in integrins and binding to extracellular matrices.
Results: In this study, we show that PMP22 expression is higher in proliferative phase than secretory phase.
Functionally, we have begun to characterize the functional significance of this expression. Previous studies have
suggested a link between PMP22 and a6 integrin, and therefore we asked whether PMP22 could associate or
potentially modulate the expression of a6 integrin. Expression of both PMP22 and a6 integrin were detectable in
endometrial epithelial and stromal cells, and we show that both proteins can associate and colocalize with each
other. To understand if PMP22 directly altered the expression of a6 integrin, we examined cell lines with
modulated levels of the protein. Overexpression of PMP22 was sufficient to increase a6 integrin surface expression
with a concominant increase in binding to the extracellular matrix laminin, while a reduction in PMP22 suppressed
a6 integrin surface expression.
Conclusion: These findings suggest a physiologic role for PMP22 on the expression of a6 integrin. We predict that
this may be important for the maintainence of endometrial integrity and to the disease biology associated with
altered levels of a6 integrin expression in the endometrium.
Background
Peripheral myelin protein 22 (PMP22) is a member of
the Growth Arrest Specific 3 (GAS3) family of tetraspan
proteins. Expression of the PMP22 gene is driven by
two alternate promoters P1 and P2 which drive tran-
scription for two transcripts containing different non-
coding exons termed 1A and 1B [1]. Although both
transcripts translate into identical proteins, the presence
of two promoters is thought to confer tissue specific
control of expression [2]. Transcripts arising from pro-
moter 1 (termed 1A) have been shown in the peripheral
and central nervous systems and are thought to be
important for myelin formation [3,4]. Transcripts origi-
nating from promoter 2 (termed 1B) have been identi-
fied in neuronal and non-neuronal tissue throughout
the body [1]. Within non-neuronal tissue, transcripts of
PMP22 1B have been identified in the epithelia of the
lungs and uterus, the choroid plexus, and the heart [5,6].
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amino-acid protein, with four predicted transmembrane
domains. The highest expression of PMP22 occurs in
Schwann cells, and there, PMP22 localizes strictly with
compact myelin [7]. Altered expression of PMP22 has
grave consequences as it is associated with certain heri-
table demyelinating peripheral neuropathies. In particu-
lar, elevated expression of PMP22 causes Charcot-
Marie-Tooth disease type 1A (CMT1A), an autosomal
dominant condition that is characterized by progressive
motor and sensory polyneuropathy [8-10]. Haploinsuffi-
ciency of PMP22 results in hereditary neuropathy with
liability to pressure palsies (HNPP) [11,12].
Outside of its role in myelin formation, studies have
implicated PMP22 in a number of cellular roles includ-
ing adhesion and the regulation of proliferation [13]. In
fact, PMP22 was first discovered as a gene upregulated
in growth-arrested fibroblasts in culture [14], and since
then, PMP22 protein has been shown to help regulate
cell spreading and regulate apoptosis in these cells [15].
Its importance in non-neuronal cells was further
expanded when it found that in epithelial cells, PMP22
localized within tight junctions and formed complexes
with integrins such as a6b4 and with the integral cation
channel P2X7 [16-18].
Several studies suggest a complex mechanism for the
regulation of PMP22 expression, and recent studies have
implicated steroid hormones in its regulation. Studies
have shown that both progesterone and glucocorticos-
teroids act as positive regulators of expression in
Schwann cells [19-21], and anti-progesterone therapy
has been shown to reduce PMP22 levels, reducing the
CMT1A phenotype [22,23]. However, outside of this cell
type, limited information is available as to hormonal
control of PMP22 expression. PMP22 has been observed
in the uterus, with high PMP22 mRNA levels in prolif-
erative stroma [24], but no studies have examined
PMP22 expression in epithelial cells of the endometrium
or throughout the estrous cycle.
In this study, we characterize the expression of human
PMP22 during the proliferative and secretory phases of
the female menstrual cycle. As previous studies have
suggested that PMP22 associates with integrins, we gen-
erated human endometrial cell lines with varying levels
of PMP22 expression and characterized their integrin
profiles. We report for the first time, the expression of
PMP22 protein in the human endometrium, with
greater expression in the proliferative phase as com-
pared to the secretory phase. Furthermore, we show that
PMP22 colocalizes a6 integrin both in vitro and in nor-
mal human tissue samples. The dichotomy of PMP22
and a6i n t e g r i ne x p r e s s i o ni nt h ef e m a l em e n s t r u a l
cycle suggests roles for the both proteins in adhesion
and state of endometrial differentiation.
Methods
Cell lines
HEC-1A, Human endometrial adenocarcinoma cells
(HTB112, ATCC, Manassas, VA) were cultured in
McCoys media, supplemented with 10% fetal calf serum,
1% L-Glutamine, 1% penicillin/streptomycin at 37°C in a
humidified 5% CO2 incubator. Cells were passaged every
3-4 days. HEC-1A cells were stably transfected with
expression plasmids for a control eGFP, or a human
PMP22 open reading frame tagged with a myc-epitope
in the second extracellular loop using FuGENE 6 (Roche
Molecular Biochemicals) per the manufacturer’s instruc-
tions. These expression vectors have been previously
described [17,25]. Stable cellular clones were selected
using Geneticin (800 ug/ml; Invitrogen, Carlsbad, CA)
and referred to as HEC-1A/Vector (empty vector con-
trol), and HEC-1A/PMP22 (PMP22 overexpression). In
some experiments, PMP22 levels were decreased by
transiently transfecting HEC-1A cells with 75 picomoles
PMP22 siRNA duplexes (SMARTpool L-010616-00-
0005; ThermoScientific, Boulder, CO) and a lipophilic
transfection reagent (Lipofectamine 2000; Invitrogen,
Carlsbad, California) for 48 hours. As a negative control,
cells were transfected with 75 picomoles scrambled con-
trol siRNA (D-001206-13-05; ThermoScientific). Cells
were harvested for Western blot, flow cytometry, immu-
nofluorescence or immunoprecipitations 36-48 hours
post-transfection, as detailed below.
Human tissue
Retrospective human tissue was obtained from the
UCLA Department of Pathology and Laboratory Medi-
cine Tissue Procurement Core Facility (TPCL) under
an exemption from the Institutional Review Board. To
validate PMP22 expression in human endometrium,
we tested total PMP22 expression in whole tissue frag-
ments of proliferative endometrium (n = 6) and secre-
tory endometrium (n = 6). As controls, we also
obtained normal frozen tonsil and lung. Tissue sam-
ples were collected and frozen in the -80 C. These tis-
sues were prepared in the hospital biorepository, and
clinical annotation is available though a database.
Cases were classified and selected based on a normal
diagnosis using the Anatomic Pathology system, and
no information regulated by HIPPA was included in
the study, which qualifies for the status of NIH
Exemption #4.
RT-PCR
All tissue was homogenized and RNA isolated using the
Qiagen RNAeasy kit per manufacturer’s instructions.
The Qiagen OneStep RT-PCR kit (Valencia, CA) was
employed using human PMP22 exon 1A or 1B [4] or
GAPDH [26]-specific primers using 1 μg RNA.
Rao et al. Reproductive Biology and Endocrinology 2011, 9:56
http://www.rbej.com/content/9/1/56
Page 2 of 11PMP22 1A: 5’- TTACAGGGAGCACCACCA-3’
PMP221B: 5’-CCACGCACCCGAGTTTGT-3’
PMP22 R: 5’-ATCATGGTGGCCTGGACA-3’
The RT-PCR conditions were reverse transcribed at
50°C for 30 min followed by PCR (25-40 cycles) at 95°C
(30 s), 55°C (30 s), and 72°C (1 min).
In order to quantititate mRNA levels, the Qiagen
QuantiTect SYBR Green RT-PCR Kit was utilized. Pri-
mers were synthesized (Real Time Primers, Elkins Park,
PA) which could recognize both transcripts of PMP22.
The 25 μl PCR reaction included 12.5 μl 2 × RT-PCR
Master Mix, 0.5 μmol/L forward primer, and 0.5 μmol/L
reverse primer. The reactions were incubated in a 96-
well plate and reverse transcribed and amplied on the
Applied Bio Systems7500 Fast System (Carlsbad, CA)
using the following primers:
PMP22 F: 5’- GTATCATCGTCCACGTC-3’
PMP22 R: 5’-GGCAGAAGAACAGGAACAGA-3’
The 2
-⊿⊿Ct method for relative quantification of gene
expression was used to determine PMP22 expression
levels [27]. Each sample was analyzed in triplicate, and
t h eh o u s e k e e p i n gg e n eG A P D Hw a su s e dt on o r m a l i z e
expression as previously described [28]. Differences
between PMP22 expression in proliferative and secretory
endometrium was determined using Mann-Whitney U
test.
Western blot analysis
Tissue or cell lines were lysed in Laemmli buffer as pre-
viously described [29] and analyzed for PMP22 expres-
sion by SDS-PAGE Western blot analysis.
Approximately 25 μg of protein were loaded per lane. In
order to detect PMP22 expression, samples were treated
for 2 h at 37°C with PNGase (New England Biolabs,
Beverly, MA) to remove N-linked glycans [30]. Proteins
were then separated by SDS-PAGE and transferred to a
nitrocellulose membrane (Invitrogen). Following trans-
fer, membranes were stained with Ponceau S (Sigma-
Alrich, St. Louis, MO) to validate the efficiency of trans-
fer. A solution of 10% nonfat milk in Tris buffered sal-
ine containing 0.1% Tween-20 was used to block non-
specific binding. Membranes were probed with rabbit
anti-PMP22 antisera [6] or with anti-b-actin antibodies
(Sigma-Aldrich). Protein bands were visualized using a
horseradish peroxidase-labeled secondary antibody
(Southern Biotechnology Associates, Birmingham, AL)
followed by chemiluminescence (ECL; Amersham Bios-
ciences). Band intensities were quantified using the NIH
program Image J. Blots were digitized using a flatbed
scanner and the band density measured using Image J.
The relative intensity of PMP22 in the three cell lines
was calculated by dividing the volume intensities over
that of the b-actin control. Experiments were repeated
three times and averaged.
Immunoprecipitations
Cells were washed in PBS and solubilized in lysis buffer
for 30 min at 4°C. (1% Nonidet P-40 containing 2 mM
phenylmethylsulfonyl fluoride, 10 ug/ml aprotinin, 2 ug/
ml pepstatin, 10 mM iodoacetamide, 0.1 mM EDTA, 10
mM HEPES, and 10 mM KCl). Lysates were sonicated
for 15 seconds and pre-cleared by incubation with pro-
tein A-agarose beads (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA). Pre-cleared lysates were incubated
overnight with Protein-A beads bound to either anti-
PMP22 rabbit polyclonal antisera (Sigma-Aldrich), anti-
a6 integrin rabbit polyclonal antibody (Santa Cruz Bio-
technology), or control rabbit sera. The beads were
washed once in lysis buffer and 50 mM Tris buffer to
neutralize salt. Immune complexes were eluted from the
beads with Laemmli buffer. Cell lysates were subse-
quently analyzed by Western blots.
Immunofluorescence
HEC-1A cells were plated onto glass coverslips (Fisher
Scientific, Pittsburgh, PA) and incubated for 24 h at 37°
C. Cells were fixed in cold methanol, blocked in 1% nor-
mal goat serum and washed in PBS with 0.01% Triton
X-100. Cells were subsequently incubated at 4°C with
PMP22 rabbit antisera (1:100; Sigma, CA), anti-a6 integ-
rin rat antibody (1:100; BD Biosciences) in a humidified
chamber. Cells were rinsed with PBS with 0.01% Triton
X-100, then incubated for 1 hour at RT with Alexa
Fluro 488-conjugated goat anti-rabbit IgG (1:50), or
fluorescein isothiocyanate (FITC)-conjugated anti-rat
IgG2a (1:450; eBiosciences). Negative controls included
incubation with secondary antibody alone. Cells were
briefly washed in PBS with 0.01% Triton X-100, double
deionized H2O, and mounted onto slides in a 3.5% n-
propyl gallate-glycerol solution. Mounted coverslips
were analyzed for PMP22 and a6 integrin localization
using confocal microscopy.
Flow cytometry
T h em e m b r a n ee x p r e s s i o no fa6 integrin, a2 integrin,
and avb3 integrin were assessed by flow cytometry.
Cells were fixed in 2% paraformaldehyde (w/v) in PBS
for 20 min on ice. Cells were pelleted and resuspended
in PBS with 2% fetal calf serum (FCS). Cells were incu-
bated with primary antibody (1:100) and incubated at
RT for 20 min. Cells were then incubated with red-phy-
coerythrin-conjugated anti-rat Ig- light chain antibody
or red-phycoerythrin-conjugated anti-mouse Ig- light
chain antibody for 20 min (0.25 ug/ 10
6 cells; BD Bios-
ciences). Negative control cells were treated similarly,
but without primary antibody. After two consecutive
washes with PBS, cells were resuspended in PBS and
analyzed with a FACScan flow cytometer (BD Bios-
ciences). Integrin expression levels were calculated as
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ware. Experiments were performed in triplicate.
Immunohistochemistry
Retrospective formalin fixed, paraffin embedded normal
human proliferative or secretory endometrial samples
were obtained from the TPCL at UCLA. Whole tissue
sections of proliferative endometrium (n=6 )o rs e c r e -
tory endometrium (n=6 ) were analyzed by immunohis-
tochemistry for PMP22 or a6 integrin expression.
Briefly, paraffin-embedded human tissue samples were
deparaffinized, blocked for endogenous peroxidase activ-
ity with 3% hydrogen peroxide, and heated at 95°C for
20 min with citrate buffer (19). The tissue samples were
blocked with normal goat serum in TBS with Tween for
10 min and stained with rabbit-anti-PMP22 polyclonal
antibody (1:100; Sigma-Aldrich) or anti-a6 integrin rab-
bit antibody (1:100; Santa Cruz Biotechnology Inc.,
Santa Cruz CA) overnight in a humidified chamber.
Slides were developed by incubation with a biotinylated
secondary antibody from the Vectastain Elite ABC kit
(Vector Laboratories) according to the manufacturer’s
protocol, followed by a diaminobenzidine tetrahy-
drochloride (DAB) substrate solution (Pierce, Rockford,
IL). Nuclei were counterstained with hematoxylin. Slides
were analyzed for PMP22 and a6 integrin expression by
microscopy.
To detail the staining of PMP22 and a6i n t e g r i ni n
proliferative and secretory endometrium, a semi-quanti-
tative analysis was performed. Each section stained was
assessed by considering the staining intensity (0 = below
the level of detection, 1, weak; 2, moderate; and 3,
strong) and the percentage of cells staining at each
intensity level (0-100%). For each tissue, an integrated
value of intensity combined with frequency was derived
using the formula: [(3x) + (2y) + (1z)] / 100 where x, y,
and z are % staining at intensity 3, 2, and 1, respectively.
Differences in expression between proliferative and
secretory endometrium were determined using a Mann-
Whitney test, where p < 0.05 was considered significant.
Adhesion assays
A standard static cell adhesion assay (15-20 min) was
performed as previously described [30]. Briefly, 96-well
plates were precoated for 2 hours at 37°C with the ECM
substrates laminin, fibronectin, poly-D-lysine (positive
control; Roche Molecular Biochemicals; 5-10 μg/ml), or
1% fatty acid-free bovine serum albumin (negative con-
trol; Sigma-Aldrich). Cells (7 × 10
4)w e r ep l a t e do n t o
the ECM in serum-free conditions and incubated at 37°
C for 30 min. Unbound cells were washed away. Bound
cells were fixed, stained with toluidine blue and then
lysed using 2% SDS (Biowhittaker, Walkersville, MD).
The resultant soluble toluidine blue was quantitated by
measuring the absorbance at 595 nm. Binding to each
ECM was performed in triplicate. Each experiment was
repeated at least three times. An unpaired Student’s t
test was used to confirm significance between HEC-1A/
PMP22, HEC-1A/Vector, HEC-1A/scrambled siRNA
control, and HEC-1A/PMP22 siRNA cells.
In antibody blocking experiments, cells were preincu-
bated with various dilutions of anti-a6 integrin [31] or
anti-a2 integrin [32] function blocking antibodies (BD
Biosciences) for 60 min at 4°C. Cells (5-7 × 10
4)w e r e
plated in triplicate into a 96-well plate precoated with
laminin or poly-D-lysine and allowed to adhere for 30
min. Unbound cells were washed away, and bound cells
were quantitated as described above. Each experiment
was repeated three times.
Results
Characterization of PMP22 expression
Previous studies have shown that PMP22 is expressed in
proliferative endometrium [24]. In order to confirm the
expression of PMP22 within the endometrium, we first
confirmed the mRNA and protein expression of PMP22
in human endometrium. PMP22 expression has been
shown to be regulated by two alternatively used promo-
ters which are located upstream of two distinct 5’ non-
coding exons (exons 1A and 1B), but both transcripts
encode for a single protein [3,33]. To characterize both
transcripts in the human endometrium, RT-PCR was
performed on select human tissue. In the endometrium,
PMP22 exon 1B mRNA expression was detectable, and
this transcript was also found in low levels in the tonsil
and in the lung (Figure 1A). Interestingly, PMP22 exon
1 Am R N Aw a so n l yd e t e c t a b l ei nt h el u n g .W en e x t
confirmed the protein expression of PMP22 using wes-
tern blot and immunohistochemical analysis. PMP22
protein expression was observed in a representative
human proliferative endometrial sample (Figure 1B) and
within proliferative endometrial epithelial and stromal
cells (Figure 1C).
In order to investigate the function of PMP22 in
endometrial epithelial cells, we monitored PMP22
expression in a panel of endometrial cancer cell lines.
Similar to the mRNA profile observed above, both
HEC-1A and Ishikawa endometrial cell lines were posi-
tive for exon 1B expression (Figure 1D). The expression
of PMP22 mRNA was below detection in RL95-2 cells.
To translate PMP22 expression in these cells, we char-
acterized the relative PMP22 protein expression by wes-
tern blot analysis (Figure 1E). PMP22 was expressed in
all three cell lines, with the highest expression observed
in HEC-1A cells. Moreover, very low levels of PMP22
were observed in the RL95-2 cells.
To investigate the role of PMP22 in endometrial epithe-
lial cells, we created a panel of HEC-1A cells with
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PMP22 overexpressed myc-tagged human PMP22, HEC-
1A/Vector expressed a vector control and baseline levels
of endogenous PMP22, and HEC-1A/siRNA expressed
PMP22-targeted siRNA and thus, reduced levels of
PMP22. In some experiments we also utilized a scrambled
siRNA control, which phenotypically resembled the vector
control. Based on semi-quantitative analysis, we obtained
a 3 ± 0.2-fold increase in the levels of PMP22 in the over-
expressing cells. In comparison, the siRNA reduced endo-
genous PMP2 by 50 ± 5% (Figure 1F). No difference in
PMP22 expression was observed between the vector con-
trol and scrambled siRNA control.
Changes in PMP22 expression regulates a6 integrin
expression
We next investigated whether PMP22 expression regu-
lated the surface expression of specific integrin subunits.
Flow cytometry was used to study select integrin
expression in HEC-1A/PMP22, HEC-1A/Vector, HEC-
1A/scrambled control, and HEC-1A/siRNA cells. Over-
expression of PMP22 resulted in increased expression of
a6 integrin compared to HEC-1A/Vector control cells
(Figure 2). Interestingly, a reduction of PMP22 expres-
sion with siRNA also reduced the expression of a6
integrin relative to vector control cells. This affect was
exclusive to a6 integrin because overexpression of
PMP22 did not alter the expression pattern of the integ-
rin a2 subunit (Figure 2). Moreover, HEC-1A/PMP22
inversely modulated the expression of avb3i n t e g r i n .
High levels of PMP22 slightly reduced the expression of
avb3 integrin, while transfection with PMP22 siRNA
slightly increased the expression of this integrin pair
(Figure 2). No differences between the vector control
and scrambled siRNA controls were observed (data not
shown).
Figure 1 PMP22 is expressed in the endometrium. (A). Frozen adult human tissues were obtained, and total RNA isolated. PMP22 exon 1B
mRNA was expressed in endometrium, lung, and tonsil tissue while expression of PMP22 exon 1B mRNA was only observed in the lung. GAPDH
mRNA was used as the loading control. (B) Tissue lysates were prepared to determine PMP22 protein expression in the endometrium. PMP22
protein was detectable in proliferative endometrium, and a representative sample is depicted. N = 6. (C) PMP22 expression was confirmed in
human proliferative endometrium using immunohistochemistry, and a representative sample is displayed. N = 6. Magnification = 400 ×. (D)
PMP22 mRNA transcripts were detected in HEC-1A, Ishikawa, and RL95-2 endometrial cell lines using semi-quantitative RT-PCR. GAPDH was used
as a loading control. (E) PMP22 protein levels in the three immortalized endometrial cell lines were detected using PMP22 antisera. b-actin was
used as a loading control. (E) To study PMP22 in HEC-1A epithelial cells, its expression was modulated through ectopic overexpression, or by
inhibition using a PMP22 specific siRNA. Vector and scrambled siRNA controls are included for endogenous expression. Expression of PMP22 was
confirmed by western blot analysis, with b-actin levels serving as a loading control.
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PMP22, HEC-1A/Vector, or HEC-1A/PMP22 siRNA cells was determined using flow cytometry. The MFI was quantitated and tabulated in the top
corner of each histogram. Upregulation of PMP22 promoted the surface expression of a6 integrin, while slightly reducing avb3 integrin.
Reciprocal effects were seen with the PMP22 specific siRNA. In contrast, no change in a2 integrin expression was observed when PMP22
expression was modulated. The experiment was repeated three times, and a representative experiment is shown. Statistical differences between
a6 integrin (B) and avb3 (C) expression were determined between the three cell lines. *, p < 0.05; Student’s unpaired t test.
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extracellular matrix proteins
One important function of integrins is to bind to extra-
cellular matrix proteins. To translate the functional
effect of changes in PMP22 expression levels on a6
integrin ligand specificity, HEC-1A/PMP22, HEC-1A/
PMP22 siRNA, HEC-1A/scrambled control, and HEC-
1A/Vector control cells were tested for their binding
capacity to the extracellular matrix laminin. Overexpres-
sion of PMP22 resulted in a significant increase in bind-
ing to laminin while in contrast, PMP22 siRNA reduced
laminin binding (Figure 3A). To confirm that laminin
binding was a6 integrin-dependent, HEC-1A cells were
incubated for 30 min with increasing concentrations of
either a6o ra2 integrin blocking antibodies (Figure 3B).
PMP22 binding to laminin was specifically disrupted
when incubated with a6 integrin antibodies, but was
not affected by a2 integrin antibodies. These results
strongly suggested that the tetraspan protein PMP22
may help regulate a6 integrin-mediated adhesion.
PMP22 and a6 integrin coimmunoprecipitate
As the flow cytometry data suggested that expression of
a6 integrin was altered by changes in PMP22 expres-
sion, we started to characterize this correlation. Initially,
we determined if PMP22 and a6 integrin could associ-
ate. Immunoprecipitations were performed in HEC-1A/
Vector and HEC-1A/PMP22 cells. In HEC-1A/Vector
and HEC-1A/PMP22 overexpressing cells, use of an
anti-PMP22 antibody pulled down both a6 integrin and
PMP22 (Figure 4A). Concordantly, pull-down with anti-
a6 integrin antibody resulted in detectable PMP22 and
a6 integrin (Figure 4A).
We also utilized confocal microscopy to examine the
co-localization of PMP22 and a6 integrin. HEC-1A/
PMP22 and HEC-1A/Vector cells were stained with
Figure 4 PMP22 and a6i n t e g r i na s s o c i a t ew i t he a c ho t h e r .
HEC-1A/Vector or HEC-1A/PMP22 cells were lysed in 1% NP-40 and
incubated with PMP22 or a6 integrin antisera. Immunoprecipations
were assessed by SDS-PAGE analysis. (A) a6 integrin and PMP22 co-
immunoprecipitate in HEC-1A/Vector and HEC-1A/PMP22 cells when
using either PMP22 or the a6 integrin antibody. Normal rabbit sera
were used to assess nonspecific pull-down of proteins. (B) Confocal
images of HEC-1A/PMP22 cells after co-immunolabeleing with anti-
PMP22 (Rhodamine) and anti-a6 integrin (clone G0H3; FITC)
antibodies. Co-localization of PMP22 protein (Rhodamine) with a6
integrin (FITC) was observed in both intracellular and plasma
membrane compartments. Scale bar, 10 μM. Insets, 50 μM.
Figure 3 PMP22 expression increased binding on laminin.( A )5×
10
4 cells (HEC-1A/PMP22, HEC-1A/Vector, HEC-1A/scrambled siRNA
control, and HEC-1A/PMP22 siRNA) were incubated in serum-free media
at 37°C for 30 min in wells coated with different extracellular matrices.
Absorbance was measured at 595 nm. Values are represented as the
mean ± SEM. for triplicate wells (*p < 0.05; Student’su n p a i r e dt test). A
representative experiment is shown; three independent experiments
yielded similar results. (B) In order to confirm that laminin binding was a6
integrin dependent, HEC-1A/PMP22 cells were incubated with indicated
concentrations of a6o ra2 (control) integrin antibodies. Samples were
then plated on laminin for 30 min, and analyzed as above.
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In HEC-1A/Vector cells, PMP22 and a6 integrin exhib-
ited a similar pattern of expression (data not shown).
Specifically, both proteins were largely retained in intra-
cellular compartments, although some protein could be
detected on the plasma membrane. Upon overexpression
of PMP22 in HEC-1A/PMP22 cells, significant levels of
both a6 integrin and PMP22 were visualized (Figure
4C). Both proteins colocalized on the plasma membrane
as well as in intracellular compartments. Thus, overex-
pression of PMP22 results in increased expression of a6
integrin at the plasma membrane, further supporting
the association of PMP22 and a6 integrin.
PMP22 is differentially expressed in the menstrual cycle
Several studies have suggested that PMP22 is regulated by
steroid hormones [20,34]. To examine its expression in the
human menstrual cycle, PMP22 mRNA levels in prolifera-
tive and secretory endometrium were quantitated using
real-time PCR. As shown in Figure 5, PMP22 mRNA levels
were significantly down-regulated in secretory endome-
trium (n = 6) when compared to those in the proliferative
phase (p = 0.02, Mann Whitney U test). On average, the
PMP22 mean expression level (1.7 ± 0.4) was 2.5 fold
higher than the mean expression of the secretory samples
(0.7 ± 0.2). These results confirm that PMP22 expression
is expressed in the endometrium and indicate that PMP22
expression is hormonally regulated in this tissue.
Localization of PMP22 and a6 integrin in human
endometrium
Endometrial sections were stained to characterize the
expression of PMP22 in proliferative and secretory
phases. PMP22 expression exhibited a phase specific
expression pattern. High expression of PMP22 was
observed in the proliferative phase (Figure 6A), and it
was markedly reduced in the secretory phase (Figure
6B). Within proliferative endometrium, intense PMP22
staining was observed in both glandular and luminal
epithelium as well as in the stroma (Figure 6A). More-
over, PMP22 localized with the basolateral interface
within glandular epithelium (arrow).
To validate the co-expression of PMP22 and a6
integrin in the endometrium, human endometrial tis-
sues were also probed for a6 integrin expression. Con-
cordantly, during the proliferative phase, expression of
a6 integrin was detectable in the glandular epithelium,
luminal epithelium, and in the surrounding stromal
cells (Figure 6C), and its expression was reduced in
secretory endometrium (Figure 6D). Moreover,
although a6 integrin showed some staining on the api-
cal surface, there was also pronounced expression on
the basolateral side during the proliferative phase (Fig-
ure 6A and 6C, arrows). The specificity of staining for
both PMP22 and a6 integrin was confirmed using con-
trol rabbit sera on a section of secretory endometrium
(Figure 6E). To quantitate the observed differences of
PMP22 and a6i n t e g r i ne x p r e s s i o ni nt h ep r o l i f e r a t i v e
and secretory phases, 12 normal endometrial samples
were scored for intensity and the percentage of cells
stained. Both PMP22 and a6 integrin were significantly
higher in proliferative compared to secretory endome-
trium (Figure 6F).
Discussion
Limited data are available on the role of PMP22 in
epithelial cell models and within the endometrium. In
this study, we confirm the expression of PMP22 in the
e n d o m e t r i u m ,a n ds h o wt h a tP M P 2 2i se x p r e s s e di n
human glandular, luminal, and stromal cells of the
endometrium. Within the menstrual cycle, PMP22
expression is greater during the proliferative phase as
compared to the secretory phase, and this expression
correlates with similar changes in a6 integrin expres-
sion. Mechanistically, both proteins associate in the
same complex as determined by immunoprecipation
and colocalize by immunoflorescence. Furthermore, ele-
vation of PMP22 expression in HEC-1A cells increases
the expression of a6 integrin; conversely, reduction of
PMP22 expression also reduces the levels of a6 integrin.
Importantly, these changes in integrin surface expression
are functionally relevant as corresponding changes in
the level of cell adhesion to the extracellular matrix pro-
tein laminin are observed.
We propose that PMP22 expression and association
with a6 integrin may be important to maintain endome-
trial integrity. a6 integrins have an important function
Figure 5 PMP22 mRNA levels inversely correlate in
proliferative and secretory phase samples. Normal proliferative
(N = 6) and secretory (N = 6) tissue was analyzed for PMP22
expression levels. GAPDH was used to normalize between samples.
Significant differences exist in PMP22 expression between normal
proliferative and secretory tissues. *p = 0.02.
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Page 8 of 11Figure 6 PMP22 and a6 integrin share a similar pattern of expression in human endometrium. (A, C) Normal human proliferative
endometrium was stained by immunohistochemistry for either PMP22 or a6 integrin, respectively. Bound antibodies were visualized using DAB,
and nuclei counterstained using hemotoxylin. Magnification: 100X. Insets depict a 400X enlargement of glandular epithelium. (B, D) Normal
human secretory endometrium was stained by immunohistochemistry for either PMP22 or a6 integrin as above. Magnification: 100X. Insets
depict a 400X enlargement of glandular epithelium. (E) Normal human proliferative endometrium was stained as above using non-specific
control rabbit sera. (F) The mean integrated intensity of PMP22 and a6 integrin protein expression was quantitated for each sample; N = 6 per
group. The error bars represent the standard error of the mean. *p< 0.05.
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Page 9 of 11in not only the attachment of cells to the extracellular
matrix, but also in the induction of cell migration and
invasion [35,36]. Within the endometrium, a6i n t e g r i n
has been shown to dimerize with both b1a n db4i n t e g -
rin. Although it is not known if PMP22 preferentially
associates with a6b1o ra6b4 integrins, the localization
of PMP22 on the basal surface of endometrial cells sug-
gests an association with a6b4 integrin [35]. This corre-
lation is supported by recent studies in clone A colonic
carcinoma cells showing that PMP22 forms a complex
with a6b4 integrin [18]. Thus, it is possible that PMP22
helps stabilize or anchor a6b4 integrins on endometrial
epithelial cells to the underlying basement membrane,
which is known to be comprised of laminin and collagen
[37,38] Intriguingly, laminin expression is rich during
the proliferative phase and reduced during the secretory
phase [38]. Additional experiments will be needed to
confirm the association and the specificity of PMP22
and a6 integrin within endometrial cells.
PMP22 belongs to the GAS3 family of tetraspan pro-
teins, and each family member shares similar primary
and secondary structures, with four relatively conserved
transmembrane regions and two significant extracellular
loops [39,40]. Interestingly, another GAS3 family mem-
ber EMP2 has been detected in the endometrium
[25,28,41]. With regard to EMP2 and PMP22, a unique
regulatory phenotype has been observed within endome-
trial cells. Whereas PMP22 is expressed predominantly
in proliferative endometrium, EMP2 expression is
greater in the secretory phase [28]. Moreover, changes
in PMP22 and EMP2 expression appear to modulate dif-
ferent integrin pairs. Overexpression of EMP2 results in
t h ei n c r e a s eo favb3-integrin whereas elevation of
PMP22 selectively increases the expression of a6i n t e g -
rin [25]. It is thus intriguing to speculate that this diver-
gent affect on integrin expression may be translated to
distinct effects on cellular function.
Importantly, our study confirms that steroid hormones
can regulate the expression of PMP22 and concordantly
the a6 integrin in non-neuronal tissue. Several studies
have shown that in Schwann cells, PMP22 can be hor-
monally activated. Both glucocortosteroids and 5a-
androstan-3a,1 7 b-diol (3a-diol), a metabolite of dihy-
drotestosteone, has been shown to transiently upregulate
PMP22 1A mRNA levels [20,21]. Moreover, anti-proges-
terone treatments have been shown to improve the phe-
notype for CMT1A through the specific reduction of
PMP22 in Schwann cells [22,23]. Our results suggest
that the regulation of PMP22 1A and 1B is different.
Given its high expression in the proliferative phase, we
would predict that estrogen may upregulate the expres-
sion of the PMP22 1B transcript in the endometrium.
Additional experiments will be needed to characterize
differences in the promoters of each transcript.
Finally, our data suggest that elevated or reduced
PMP22 levels could result in an altered repertoire of
integrin isoform expression and perhaps specifically with
a6 integrin. As dysregulation of a6 integrin has been
implicated in disease biology of the endometrium,
PMP22 may be an underappreciated potential target for
diseases such as infertility, endometriosis, and endome-
trial cancer [35,42,43].
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